Biomedical materials have been developed for facilitating tissue regeneration and healing enhancement. Although research on biomedical materials has made great progress in material innovation and preclinical testing, the bottleneck is their translation from research and development to clinical applications; that is, the current rate of product registration and industrialization is low, which directly affects their clinical applications. In this paper, we introduce the basic features of biomedical materials towards the making of medical products and the experiences of our group in research and clinical translation of biomaterials for bone-tissue regeneration in the last few years. Based on our experience, we propose that the translational medicine platform (TMP) is an effective route to facilitate the progress of biomedical materials from bench to bedside. Moreover, from the viewpoints of scientific technology and management, the functions of TMP were also addressed. Relationships among TMP, research institution, enterprise, and government were also explored from the viewpoints of technological innovation, chemical engineering integration, fund raising, and management. This paper provides a theoretical and practical reference for clinical translation of biomedical materials.
Introduction
Biomedical materials are a group of special functional materials that aid in the diagnosis, treatment, recovery or replacement of diseased or damaged tissues or organs, and promoting functions of physiological systems. The use of medical materials not only saves the lives of many patients and significantly decreases the death rate of patients with various medical conditions, such as wounds and cancers, but also plays an important role in improving the quality of life and health of patients. Health issues have become a great challenge worldwide. Because of the more frequent occurrence of diseases, natural disasters, traffic accidents, and population ageing, the requirement for biomedical materials in clinical applications is rapidly growing, and biomedical instruments are predicted as a new growth point in the world economy [1, 2] .
There are 60 million physically challenged people out of the 1.3 billion people living in China. According to available statistical data, there are 70 million patients with osteoporosis, more than 0.3 billion people with various dental problems, 0.15 million patients undergoing joint replacement surgery annually, millions of people undertaking cosmetic surgery, and more than 20 million with coronary heart disease or cardiovascular disease. Therefore, the demand for biomedical materials is very high, which is expected to increase with the further development of rural markets [2, 3] . Unfortunately, in China, less than 5% of biomaterials and medical instruments are manufactured domestically. In addition, the availability of products required for making these biomaterials is often limited and some products may result in less satisfactory treatment outcome. Meanwhile, huge financial profits and market potential have greatly attracted overseas' companies into domestic markets, and thus the percentage of high-level products supplied by domestic enterprises are significantly reduced. Consequently, domestic enterprises are experiencing great frustration and the cost for medical treatment is subsequently increasing. To solve these problems completely, independent research and development (R&D) of high-performance biomedical materials is urgently needed.
R&D of biomedical materials towards clinical translations
Translational medicine in orthopaedics has become a focus of local and international medical communities, especially in the development of biomedical materials [4e6]. Biomedical materials have been developed in China for more than 20 years. However, both fundamental research and technological development are far behind that of the developed countries. In the past few years, under the support of National Natural Science Foundation of China, National Basic Research Programme of China (973 Programme), and National High Technology Research and Development Programme (863 Programme), the research of biomedical materials in China has made great progress from low-level repetition to programme-oriented and cuttingedge development in some aspects of this discipline. For many years, the biomaterials research group of the East China University of Science and Technology (ECUST) has focused on the clinical demand-driven development and R&D of bone-tissue-repair materials. We also have tried our best to promote our research outcomes towards industrializations and clinical applications. For example, based on the biology of wound healing and the selfrepairing potential of the human body, we have proposed and developed a bioreactor that possesses the function of in situ-guided tissue regeneration by synergistic effects of biomaterials and growth factors. In this reactor, tissue cells can adhere, grow, and differentiate on the scaffold surface, thereby promoting new bone formation accompanied by the degradation of the scaffold materials [7, 8] .
Our group is the first to study calcium phosphate cement (CPC) in China [9e11]. Based on the theories and methodologies in chemical engineering, the transformation mechanisms of specific kinds of ultrafine calcium phosphates in liquidesolid systems were thoroughly investigated. We successfully prepared CPC with high purity and high activity by a series of processes, including micromixing, heterogeneous nucleation, heat treatment, pore formation at room temperature, and control of the degradation rate to meet biological and physiological needs in bone-defect repair. In addition, our group systematically investigated the hydrating and hardening mechanisms of CPC. Based on these basic studies, osseointegration characteristics and degradation mechanisms of the prepared CPC were confirmed by in vivo animal experiments. With the superior properties of self-setting, easily shaped capability, biocompatibility, and biodegradability, we have successfully obtained the first product registration for CPC materials certified by the State Food and Drug Administration (SFDA). Our CPC has been applied in more than 500 hospitals and in over 240,000 patients in big cities such as Beijing and Shanghai. Furthermore, a series of CPC-based bone-tissue-repair materials, including drug-loaded CPC, injectable CPC, and porous CPC, has been developed ( Fig. 1 ).
To further improve the therapeutic efficacy, especially for patients with large or critical bone defects and for elderly patients with poor bone-regeneration potential, recombinant human bone morphogenetic protein-2 (rhBMP-2)-loaded bone-tissue scaffold has been developed [12, 13] . Using genetic engineering technology, rhBMP-2 with high purity and high bioactivity has been successfully prepared by optimization of Escherichia coli expression system, construction of engineering bacteria, and expression and purifying technologies and has been patented in the United States [12] . In addition, the scale up (30 mg/batch) of rhBMP-2 was achieved as well. Based on these results, we have systematically studied the effects of the chemical composition, surface/interface structure of the materials, and other small molecular medicines on microstructure, presentation, and bioactivity of rhBMP-2. Based on these fundamental studies, we have fabricated rhBMP-2/CPC scaffold with enhanced osteogeneration potential [13] . Up to now, we have applied this new rhBMP-2/CPC scaffold for 68 patients with limb fractures and vertebral fusion. Our CPC has shown great clinical efficacy in enhancing bone regeneration. The rhBMP-2/CPC has also been authorized by the SFDA [armed (2013) No. 3460199].
After over 10 years, we have indeed realized that the road from R&D to clinical translation needs multidisciplinary teams to work together for many years and the barriers for successful clinical translation are the product development and registration.
Consideration of the clinical translation of biomedical materials
The clinical translation of biomedical materials can not only effectively relieve the patients' pain and improve patients' life quality, but it can also contribute to remarkable socioeconomic profits. By contrast, the financial profits gained from clinical applications and the experience from clinical practice can further promote the fundamental research of biomedical materials and their R&D through virtuous cycle between basic research and clinical applications. However, this is a very complicated process and requires efforts from many participating institutions, industries, and regulatory bodies. Based on the experience in promoting industrialization of self-setting CPC by the ECUST, we will discuss the difficulties, experiences, and lessons in the clinical transformation process of biomedical materials [14] .
Characteristics of the biomedical materials and their main obstacles in the process of transformation from bench to bedside
Biomedical materials application is a relatively new branch of science with a multidisciplinary nature involving biology, materials, chemistry, and medicine. The commercialization of biomedical materials often includes laboratory research, pilot experiments, clinical trials, drug-approval programme, product registration, and marketing or clinical applications. Thus, the transformation of biomedical materials to clinical applications requires a tight cooperation among government, research institutions, companies, and hospitals.
However, there are some critical issues that need to be addressed before transforming biomedical materials to clinical applications. First, research institutions, hospitals, and enterprises are independent of each other. The connection between basic research and clinical application is still poor, and thus the technology developed in a research laboratory cannot meet the demands of clinical needs. Second, chemical engineering is comparatively weak and effective engineering integration is desirable. Third, the absence of platform organizations with strong research capacity, familiar with relative law and regulatory requirements and market operation at the same time, results in the disconnection of research and application. Fourth, although the translation from research to clinical application is a long-term task, long-term strategic support for funds from government or enterprises with long-term development visions is often limited, which is in fact rare in developed countries. All these are critical obstacles in the effective translation from fundamental research to clinical application, and thus the rate of clinical translation of biomedical materials is very low. Low clinical translation rate and the long duration involved in obtaining product registration are the major obstacles, and these create a huge gap between research investment and the health demand in China. Therefore, great attention must be paid to find a solution to shorten the period of translation of fundamental research to clinical application, thereby accelerating the clinical translation in the field of biomedical materials.
Translational medicine platform
A good approach to bridge the gap from basic research to clinical application is to establish a translational medicine platform (TMP). The core of the TMP is to establish effective ties among basic medical researchers, public health workers, and doctors, particularly to translate the biomedical research results to suitable disease prevention, diagnosis, treatment, and prevention methods effectively. Therefore, the mission or objective of TMP, from a technical viewpoint, is to build a bridge between research institutions and enterprises. Efficient translation and application centres or laboratories should be established, which mainly takes care of the technology development in the process of medical translation and facilitates the conversion of product R&D to clinical application [15, 16] . The detailed process is summarized in Fig. 2 . By contrast, from a management's viewpoint, an administration department should be established, including commission of experts, management office, and outreach coordination office, which mainly coordinate the relationships among hospitals, research institutions, and enterprises to create a novel market-oriented technological innovation, strengthen the integration process and the connection between scientific technology and management. This will facilitate the formation of an advanced and highly efficient management model.
TMP-based clinical translation for biomedical materials
The TMP-based clinical translation process for biomaterials will be discussed regarding the following points:
Focussing on clinical application and launching marketoriented technological innovation
The source of biomaterial innovation is from the clinical needs-based market information and feedback from existing clinically approved biomaterials. Only by close followup of the market situations and good understanding of the market demand, together with a series of outbreaks in key technology or other related fields, the products designed can meet the requirement of clinical applications and market needs. This is essential to provide sustainable development of enterprises and may subsequently help the enterprises to expand and get into a revenue-generation cycle. Therefore, from this viewpoint, R&D of biomedical materials must be geared towards the demands of the market and strengthen the basic application research. Generally speaking, science and technology innovation needs both knowledge innovation and technology innovation, and technology innovation often comes from our knowledge innovation ( Fig. 3 ). During this process, academic and research institutions are the core of fundamental research and knowledge innovation, and enterprises are the centre of technology innovation. Subsequently, science and technology innovation needs close cooperation and joint efforts from research institutions and enterprises.
Here, we will demonstrate a successful collaborative innovation between research institutions and enterprises using an example of a technological innovation in osteoinductive bone-repair materials developed in the ECUST. With the clinical demands on highly bioactive bone-repair materials, our group has carried out basic research and knowledge innovation from the controllable preparation of the composite materials, maintenance of bioactivity with sustainable release of incorporated growth factors, synergistic action of small molecules, and immobilization of growth factors onto the designed biomaterial matrix. Meanwhile, Shanghai Rebone Biomaterials Co. Ltd., which has been formed as a spin-off company of the ECUST and shares the R&D and translational duties with the ECUST, mainly focuses on the industrialization, scale up of the matrix preparation and growth factors, and so on ( Fig. 4) .
Emphasizing engineering and technology integration and improving the comprehensive properties of biomedical materials
The first step in engineering research of the biomedical materials is scale up of the synthesis of biomaterials. Usually, the fabrication of biomedical materials mainly includes material preparation and activation, such as assembly of growth factors, which is very different from traditional translational engineering. The purpose of the regulation and optimization of biological materials is to improve the biological performances and safety of the materials, and not just the conversion rate and selectivity in traditional chemical engineering. The regulation of the materials' performances and engineering factors often interact with each other, which makes the R&D become more and more complicated. The conventional chemical process of a product mainly contains three elements, namely, materials, processing rate, and product conditions. The product performance is mainly modulated by chemical composition and the key to the scale up is selectivity and yield during the process. However, the development and active assembly of biomedical materials often involve five elements, namely, materials, microstructure, biological activity, processing rate, and product conditions. The final application performance not only depends on its chemical composition, but also relies on its microstructure and biological activity. Therefore, the final purpose of the preparation process is chemical composition, bioactivity, and application performance of the materials. The economic benefits of the process depend on productivity and performance of the products. Furthermore, the materials' composition, threedimensional structure, interfacial surface, and bioactive factor often have an effect on blood coagulation, bioactivity, and degradation in vivo. Therefore, it is very difficult to take a single element into account to represent the entire process. We must explore the effects of composition of materials, three-dimensional structure, surface status, and bioactive factors together during the process of research, which directly leads to a much more complicated process involving preparation of materials, activity assembly, mixed flowing, and transferring mass. Therefore, from this viewpoint, it is necessary to combine traditional chemical engineering with the features of biological materials. The possibility of industrialization must be considered from the selection of methods and raw materials.
Besides the scale up of biomedical materials, a successful clinical translation must emphasize the safety and operability of the biomaterials, and their clinical indications. In addition, the related supporting equipment must also be considered. Therefore, the entire process is systematic engineering.
Combining the technological and investment factors to solve the funding shortage in the process of industrialization Because of the long periods involved in R&D and clinical translation, as well as the high risk involved, government and big enterprises or companies often invest very little in the early stages. Therefore, insufficient funding is one of the main factors restricting the successful translation of biomedical materials into clinical applications.
From this point, the government should strengthen investment and take different measures depending on the features during the various stage of the development. To realize it, the government can deploy the following three important programmes: cultivating innovative technology, facilitating technology integration, and promoting industrialization. The government also should develop various preferential policies for importing advanced technologies and try best to guide the investment effectively from all aspects of the society. At the same time, government should also pay attention to the long-term strategic investment to normalize risky investment system and promote efficient combination of technological elements and financial investments.
The relevant enterprises should also initiate multiinvestment systems to raise funding and provide a foundation on which to develop and grow the biomedical materials field. Only by promoting a combination of technology and funding factors, fluxion of funds and property rights, can the intelligence, technology, cash, and management be effectively integrated. As a result, the technology of the biomedical materials can be brought out and the funding obstacles during the industrialization process can be solved.
Establishing an advanced management model in line with the development of biomedical materials Because the R&D of biomedical materials involves high costs and long cycles in the translation process, it can be easily impaired by external social and economic environments. Therefore, the related enterprise should fully understand the industrial internal and external conditions, and carry out an advanced management model to achieve effective organization and management. This is very important to promote industrialization of biomedical materials.
First, clinical translation of biomedical materials requires great attention to the relative laws and ethical issues during the whole process. The final application of the biomedical materials is for the human body, and the evaluation of biomedical materials often includes safety, therapeutic effect, and the medical ethical issue relative laws and international practices. Therefore, the biomedical enterprises should always pay attention to the biomedical material-related constructional strategy carried out by the government and try to avoid malpractice during the process of industrialization.
Second, with regard to daily management, enterprises should closely or intensely control the quality of products and test the products carefully, ensure the safety of products and undertake the responsibility and obligation for the final quality of the products. In the meantime, the company should also establish a novel management model in line with the development of a high-tech enterprise. By these strategies, the enterprise can ignite the passions of talents and backbone and reduce the risk in the process of clinical translation.
Optimizing supervision of the government By studying and referring the advanced management experience of the developed countries, we should strengthen the administrative supervision, improve the level of management, and standardize the market order. Considering the specific conditions in China, we should build a unified, standardized, internationally monitored evaluation system in the field of biomedical materials. For example, various evaluation methods should be taken for different products, and gradually improve the tightly and one-side-oriented phenomenon. First, we should change the current situation, where the registration review is strict and daily supervision is relatively loose after the product has been certified. The key problem is not certification, but close supervision in the ensuing operation and daily management. Therefore, we must combine the rigorous market certification with strict supervision. Only by combination, the contradiction between governmental effective supervision and enterprise development can be effectively resolved. In addition, the safety of the biomedical product can also be ensured.
Second, we should change the attitudes towards the domestic products. The domestic products are as important as the products fabricated for export. For the independently innovative domestic products, we should build a priority-review and fast-review programme and break out the boundary in product registration and approval. Moreover, by clearing the obstacles of circulation process of biomedical materials and cleaning up the abnormal phenomenon during the bidding process, a better market order should be established.
Third, for promoting the development of the technology and market in the field of biomedical materials, the government should build a domestic and international network to recruit talent, technology, resources, and management. By doing this, independent R&D centres, industry-specific common technology, and top-level talent and resources can be formed, which will subsequently result in the healthy development of biomedical materials in China.
Strengthening the role of the product registration consultation company
The review and registration by SFDA is the most difficult and tough step for the translation of research outcome to clinical application. Different products have different evaluation requirement and standards. Therefore, to speed up the process, the TMP should establish a registration consultation company, and the researcher and enterprise should strengthen the communication with them. The registration consultation company should provide the guideline of all related policies and laws, offer assistances in file preparation, safety evaluation, and so on. The consultation company can also help the company to run registration smoothly and obtain reliable results, and thus the registration process efficiency of biomedical materials will be improved. The most important objective of this consultation company is to ensure that the research result registration is easier and efficient.
In summary, China is experiencing a critical time in building a well-off society and stepping into the developed country. We should aim at the clinical demands of the country and build up TMP, where our research institutions, enterprises, and clinics shall collaborate efficiently and play their own unique role in R&D and clinical translation of biomedical materials. This collective effort will form sustainable self-innovation ability for developing biomedical materials and shorten the gap or time between R&D and industrialization. By creating innovative and novel ideas, new methods and a new strategic programme, we can make R&D of clinically orientated biomedical materials become one of the national's high-and new technology industries.
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